Gracell Biotechnologies Inc. American Depositary Shares
GRCL
GRCL was delisted on the 21st of February, 2024.
34 hedge funds and large institutions have $75.1M invested in Gracell Biotechnologies Inc. American Depositary Shares in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 8 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
3% less funds holding
Funds holding: 35 → 34 (-1)
13% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 8
63% less capital invested
Capital invested by funds: $203M → $75.1M (-$128M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$5.32M |
| 2 |
CII
Capital International Inc
Los Angeles,
California
|
+$1.99M |
| 3 |
PBA
Paradigm Biocapital Advisors
New York
|
+$811K |
| 4 |
BlackRock
New York
|
+$494K |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$343K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital International Investors
Los Angeles,
California
|
-$12.6M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$10.9M |
| 3 |
FM
Frazier Management
Seattle,
Washington
|
-$10M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
-$2.97M |
| 5 |
National Bank of Canada
Montreal,
Quebec, Canada
|
-$561K |
GRCL Hedge Fund Activity: Q1 2022 in Review
34 institutional investors reported a position in Gracell Biotechnologies Inc. American Depositary Shares (GRCL) for Q1 2022, worth a combined $75.1M — down 63% from $203M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of GRCL and 7 opened new positions — a net loss of 1 holder — while 9 trimmed existing stakes and 12 added.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $5.32M. The largest seller was Capital International Investors, exiting entirely with an estimated $12.6M sold.
- 34 institutional investors held Gracell Biotechnologies Inc. American Depositary Shares (GRCL) as of Q1 2022, down from 35 in Q4 2021.
- Funds reported $75.1M of Gracell Biotechnologies Inc. American Depositary Shares stock for Q1 2022, down 63% quarter-over-quarter.
- 7 funds opened new Gracell Biotechnologies Inc. American Depositary Shares positions in Q1 2022 and 8 closed out, a net change of -1 holder.
- The largest Gracell Biotechnologies Inc. American Depositary Shares buyer in Q1 2022 was EcoR1 Capital, an estimated $5.32M added.
- The largest Gracell Biotechnologies Inc. American Depositary Shares seller in Q1 2022 was Capital International Investors, an estimated $12.6M sold.
Based on aggregated 13F filings for Q1 2022.